Sterile compounding for home therapy

September 4, 2025

Introduction to Sterile Compounding for Home Therapy

Sterile compounding in home therapy is an essential aspect of modern healthcare, allowing patients to receive necessary medications tailored to their needs in a safe environment outside the hospital. This practice involves the preparation of compounded sterile preparations (CSPs) that maintain the highest standards of sterility, safety, and accuracy. In this article, we delve into the practices, regulations, and standards that govern sterile compounding, offering insights into how they ensure effective patient care and safety in home environments.

Understanding USP 797 Guidelines

What are the USP 797 guidelines for sterile compounding?

The USP 797 guidelines establish vital standards for the preparation of compounded sterile preparations (CSPs) in pharmacy settings. These guidelines aim to ensure patient safety and minimize possible risks associated with sterile compounding practices. Under these regulations, CSPs are organized into three risk categories: low, medium, and high. Each category accounts for different factors, including the compounding environment and sterility testing requirements, while also assigning specific Beyond Use Dates (BUDs) for each type.

Updates effective from November 1, 2023

Beginning November 1, 2023, an updated version of USP 797 will come into effect. This revision includes some key modifications, such as a refined definition for immediate use compounding, which now allows for a maximum BUD of 4 hours and limits the preparation to only three different sterile products. The updated guidelines enhance cleaning and disinfection protocols, mandating the use of sterile cleaning solutions and sporicidal agents. Additionally, personnel handling the compounding process must complete annual training to maintain competency, with a strong focus on contamination prevention and quality assurance of medications.

Categorization of CSPs

CSPs are classified into three categories based on contamination risk and preparation complexity:

Risk Level Description Specific Considerations
Low Simple preparations in controlled environments Typically involve one or two sterile products in a cleanroom setting, requiring basic sterility protocols.
Medium More complex preparations Involves multiple ingredients or longer preparation times; requires more rigorous testing.
High High-risk preparations Often includes hazardous drugs or preparations that must meet stringent sterility standards to prevent patient harm.

The classification helps determine the appropriate protocols to ensure the safety and quality of CSPs prepared for home infusion therapy.

The Role of Home Infusion Therapy

Can infusion therapy be conducted at home?

Yes, infusion therapy can be conducted at home through a process known as home infusion therapy. This method involves the intravenous or subcutaneous delivery of medications or biologicals. Essential components include:

  • The drug : Prescribed and tailored to meet patient-specific needs.
  • Equipment : Such as infusion pumps, requiring careful setup and monitoring.
  • Supplies : Including sterile tubing and catheters for safe delivery.

Additionally, professional nursing services are typically involved to ensure proper administration and patient care at home.
Under the 21st Century Cures Act, Medicare introduced a benefit for home infusion therapy effective from January 1, 2021, which covers professional services related to this therapy.

What professional services are involved in home therapy?

The provision of home infusion therapy engages multiple professional services:

  • Pharmacists : They prepare compounded sterile preparations (CSPs) and ensure compliance with rigorous standards, specifically USP <797>, to safeguard patient health.
  • Infusion Nurses : They educate patients on the administration of therapies and monitor ongoing treatment, playing a crucial role in managing patient care.
  • Pharmacy Technicians : They assist in the compounding processes, ensuring that the medications are prepared under sterile conditions, critical for patient safety.

How is care coordinated in home infusion therapy?

Coordination among care providers is vital for the success of home infusion therapy. Key aspects include:

  • Thorough patient assessments : Before initiating therapy, pharmacists and nurses evaluate the patient's suitability for home care.
  • Communication : Clear documentation and frequent communication between pharmacists, nurses, and healthcare providers ensure a seamless treatment journey.
  • Ongoing monitoring : Regular follow-ups are crucial to adjust therapies as needed, ensuring the highest quality of care throughout the patient's treatment process.

Home infusion therapy not only offers flexibility for patients but also empowers them to receive essential medications safely within the comfort of their homes.

Common Medications for Home Infusion

Which drugs are commonly infused at home?

Home infusion therapy involves a diverse range of medications tailored to meet individual patient needs. Common medications infused at home include:

  • Antimicrobial Therapies :

    • Acyclovir : Used to treat viral infections.
    • Meropenem : A broad-spectrum antibiotic for severe infections.
    • Amikacin : An aminoglycoside antibiotic effective against resistant infections.
    • Vancomycin : Essential for combatting vancomycin-resistant pathogens.
  • Antiemetics :

    • Ondansetron : Helps manage nausea and vomiting, particularly for chemotherapy patients.
    • Granisetron : Another antiemetic effective in similar situations.
  • Cardiac Therapies :

    • Dobutamine : Used to treat heart failure and low cardiac output.
    • Furosemide : A diuretic for managing fluid retention and heart conditions.
  • Corticosteroids :

    • Dexamethasone : Reduces inflammation and treats various conditions.
    • Methylprednisolone : Another anti-inflammatory medication.

Additionally, home infusion patients may receive hydration solutions and total parenteral nutrition (TPN), ensuring they maintain nutritional needs while managing their daily routines comfortably at home. The flexibility of these therapies significantly contributes to improved quality of life for patients requiring ongoing treatment.

Maintaining a Sterile Compounding Environment

What are the requirements for sterile compounding environments?

Maintaining a sterile environment is critical in the preparation of compounded sterile preparations (CSPs). Key requirements include:

  • Air Quality Standards : Compounding areas must meet an ISO level of 5 or better. This is vital to ensure that the cleanliness and airborne particle levels are controlled effectively.
  • Airflow Management : Unidirectional airflow is essential, supported by HEPA filtration systems. Regular airflow studies are conducted to maintain the integrity of the air quality, which is crucial for preventing contamination.
  • Personal Protective Equipment (PPE) : All personnel involved in compounding must wear appropriate PPE to minimize any risk of contamination during the compounding process.
  • Labeling Standards : CSPs must be labeled clearly with a Beyond-Use-Date (BUD) to assure that the preparations are used within safe time frames, adhering to cGMP and USP <797> guidelines.

How is quality assurance achieved in sterile compounding?

Quality assurance in sterile compounding primarily involves several systematic practices:

  • Routine Environmental Monitoring : Regular checks for viable and nonviable particles, along with temperature and pressure monitoring, help to maintain sterile conditions.
  • Cleaning Protocols : Strict adherence to cleaning and disinfecting protocols is critical to prevent contamination of the compounding area.
  • Documentation and Compliance : Accurate documentation of all compounding processes and adherence to safety standards ensure that CSPs meet regulatory requirements.

Overall, these standards and practices bolster the safety and efficacy of CSPs used in home infusion therapy.

ASHP Guidelines for Sterile Compounding Practices

What are the ASHP guidelines on compounding sterile preparations?

The ASHP guidelines on compounding sterile preparations outline the critical responsibilities of pharmacy personnel—primarily pharmacists and pharmacy technicians—focused on ensuring the quality and safety of compounded sterile preparations (CSPs). Revised from the 2000 guidelines, they align with USP Chapter <797>, categorizing CSPs into three risk levels: low, medium, and high. Each category comes with specific aseptic technique and monitoring requirements to mitigate contamination risks.

In addition to categorization, the guidelines emphasize legal and regulatory compliance, highlighting the necessity of stringent cleaning procedures and environmental monitoring. Adhering to these standards is crucial for upholding cleanliness and sterility in compounding environments. ASHP also provides resources and training tailored to help pharmacies conform to updated standards, particularly the latest revisions effective as of November 1, 2023.

What roles do pharmacy personnel play in sterile compounding?

Pharmacy personnel, especially pharmacists and technicians, play a pivotal role in sterile compounding. They must be well-versed in aseptic techniques and the specific challenges of compounding in home care settings. Staff must undergo training that includes hand hygiene, cleaning and disinfection, and documentation of compounding processes.

Moreover, they are responsible for implementing protocols that effectively manage the complexities associated with longer storage times and multi-ingredient preparations, such as total parenteral nutrition (TPN). Through this rigorous training and adherence to ASHP guidelines, pharmacy personnel can significantly enhance patient safety and the efficacy of infusion therapies.

Understanding the 10% Rule in Sterile Compounding

What is the 10% rule for sterile compounding?

The 10% rule for sterile compounding is a critical guideline designed to ensure accurate dosing of injectable medications, especially in intravenous (IV) solutions. This rule states that if the volume of added medications exceeds 10% of the total volume indicated on the bulk solution container, an adjustment must be made by removing an equivalent amount of fluid from the IV bag.

This practice is vital for maintaining the correct drug concentrations within the solution. An overfill can lead to significant variations in the actual dosing, potentially resulting in patient safety risks and reduced efficacy of treatment. For instance, mismanagement of overfill has previously caused scenarios where patients received diluted chemotherapy solutions, impacting their treatment outcomes.

To mitigate such risks, healthcare organizations are strongly encouraged to standardize preparation methodologies, improve documentation protocols, and enhance labeling practices in sterile compounding environments.

Accurate dosing of medications

Adhering to the 10% rule helps pharmacists and technicians ensure that every compounded sterile preparation is both safe and effective. Accurate dosing is particularly important in sensitive patient populations, where precise medication administration can mean the difference between successful recovery and adverse effects. By implementing stringent controls and training for personnel in sterile compounding techniques, home infusion providers can safeguard against the pitfalls of improper dosing and maintain high standards of patient care.

Conclusion: The Future of Home Therapy Through Sterile Compounding

As the demand for home healthcare continues to grow, so does the need for sterile compounding services that can deliver safe, effective, and personalized care outside traditional medical settings. The evolving standards and guidelines ensure that medications are prepared with precision and care, safeguarding patient health and enhancing quality of life. By adhering to these stringent practices and continuously improving their processes, home infusion pharmacies can meet the diverse needs of their patients, providing critical treatments that help manage complex conditions from the comfort of one's home.

References

Dialysis center staff coordinating phosphate binder supply with a pharmacy partner
August 11, 2026
What dialysis centers should look for in a phosphate binder supply partner: reliable delivery, formulary breadth, insurance support, and coordination.
Renal dietitian reviewing phosphate levels with a dialysis patient
August 11, 2026
How hyperphosphatemia is managed in ESRD dialysis patients, diet, dialysis, and phosphate binders, and why reliable binder supply keeps therapy on track.
July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Show More